Latest / Pharmacy Podcast Network / Bup Basics: Buprenorphine for Pain Management | Geriatric Pharmacy Focus
Transcript
- 0:07Speaker 1: Thanks for listening to the Pharmacy Podcast Network. We have
- 0:25Speaker 1: an aging population taking more medications than ever before. On
- 0:29Speaker 1: this podcast, I will interview experts in geriatric medicine to
- 0:33Speaker 1: gain insights so we can provide optimal care to patients
- 0:35Speaker 1: in their golden ears. I'm your host, doctor Tammar Ruggles,
- 0:38Speaker 1: and this is the Geriatric Pharmacy Focus. Hello listeners, Welcome
- 0:46Speaker 1: back to the Geriatric Pharmacy Focus. I am so excited
- 0:49Speaker 1: today to have a wonderful guest, doctor sing Ping Chow,
- 0:53Speaker 1: who if you follow him on LinkedIn, you know he
- 0:55Speaker 1: produces some awesome content on pain management. And about a
- 0:58Speaker 1: year and a half ago, I have doctor Laura mayer
- 1:01Speaker 1: hun go on talking about opioid stewardship and she briefly
- 1:04Speaker 1: brought up the but trans patch and I had not
- 1:07Speaker 1: seen that in my nursing home patients as a way
- 1:10Speaker 1: to manage pain, and she kind of opened my eyes.
- 1:14Speaker 1: I guess you could say, to the but trans patch
- 1:16Speaker 1: and bupernorphine and my nursing home patients for pain management
- 1:20Speaker 1: and kind of the benefits that that medication brings. So
- 1:23Speaker 1: I've been looking more into it and then found Sinping
- 1:26Speaker 1: on LinkedIn who also produces awesome content on Buepernorphine and
- 1:30Speaker 1: has kind of helped me with some of the guides
- 1:32Speaker 1: he has put out. So if you're not falling on LinkedIn,
- 1:35Speaker 1: do that now. But he is a pain management specialist
- 1:38Speaker 1: at the VA at the Bay Pines, CA in Florida,
- 1:42Speaker 1: and so Sinping, welcome and please tell us a little
- 1:45Speaker 1: bit about yourself.
- 1:46Speaker 2: Thank you, Thank you, Tamara, thank you so much for
- 1:49Speaker 2: introducing and inviting me to the podcast. I'm very excited.
- 1:55Speaker 2: So my name is Sinping. I am an inpatient pain
- 1:58Speaker 2: management pharmacist. So I just want to make a little
- 2:00Speaker 2: disclaimer before I go into the podcast today. So everything
- 2:06Speaker 2: that I'm mentioning today will be the opinion of my
- 2:08Speaker 2: own and it does not reflect any opinion.
- 2:12Speaker 3: To my employer.
- 2:13Speaker 2: So with that, I want to say that my role,
- 2:17Speaker 2: my current role, has been rapidly evolving over the last
- 2:22Speaker 2: two and.
- 2:22Speaker 3: A half years.
- 2:23Speaker 2: So when I first started my position, I was having
- 2:29Speaker 2: some sort of console structure in place, and at the
- 2:34Speaker 2: time I was helping out physicians and patients who are
- 2:39Speaker 2: really struggling with their pain management.
- 2:43Speaker 3: And so after some.
- 2:45Speaker 2: Time doing more of a console based service, I realized
- 2:50Speaker 2: that the reach was not enough. So at that time
- 2:54Speaker 2: I was like, I need to really get almost like
- 2:59Speaker 2: deeper into the system and really see what is how
- 3:04Speaker 2: can I help even more So, after I you know,
- 3:09Speaker 2: realized that the consult service is in getting as much traction,
- 3:13Speaker 2: then I started doing table.
- 3:16Speaker 3: Rounds with the hospitalists.
- 3:18Speaker 2: And at that time, after I started doing that, I
- 3:22Speaker 2: really gain more appreciation and understanding of the practice, really
- 3:27Speaker 2: the granular practice and how they think about how they
- 3:32Speaker 2: think through pain management, how do they approach medication management
- 3:36Speaker 2: and opioids. And after that that really opens my eyes
- 3:40Speaker 2: more because only when you understand how they practice, how
- 3:46Speaker 2: they see opiate management, then you can actually address those
- 3:52Speaker 2: root cause and provide the education. So that was my
- 3:56Speaker 2: transition from console to more of a table round with hospitalists,
- 4:02Speaker 2: and then afterwards I feel like I can do even
- 4:06Speaker 2: more than just rounding with hospitalists, and now I am
- 4:11Speaker 2: transitioning more to doing opiate stewardship and really looking at
- 4:17Speaker 2: like a systemic level in the internal medicine wards and
- 4:23Speaker 2: how can I address the IV opiod us and how
- 4:26Speaker 2: can I really optimize the opiates and non opiods for
- 4:31Speaker 2: patients for better care. So it's been rapidly evolving just
- 4:36Speaker 2: in the last two and a half years, and I'm
- 4:38Speaker 2: very excited to do what I'm doing because there's the
- 4:42Speaker 2: directions and the potentials and possibilities are limitless.
- 4:46Speaker 3: So if I can share three things.
- 4:50Speaker 2: That makes us important and really why we're such an
- 4:54Speaker 2: integral part to the healthcare system, and how we can
- 4:59Speaker 2: really add address the current opiate crisis in the current
- 5:03Speaker 2: landscape in America, I would say the first thing is
- 5:07Speaker 2: that many of us can recognize the opio dose, but
- 5:13Speaker 2: not many of us, let it be clinicians or pharmacists
- 5:17Speaker 2: will be able to comment or clinically evaluate a dose.
- 5:22Speaker 2: And what I mean by that is when I percept
- 5:26Speaker 2: pharmacy resident or medical resident, I love asking them this question,
- 5:31Speaker 2: how would you comment as certain opiod dose? And I
- 5:35Speaker 2: love using oxy code on thirty milligrams because that's kind
- 5:37Speaker 2: of like moder to a high dose as a single
- 5:41Speaker 2: thirty milligram dose. But I want to see what kind
- 5:45Speaker 2: of rationale or what kind of reasoning do they have
- 5:49Speaker 2: to when I asked them to comment on it, And
- 5:53Speaker 2: so for the most part, I would get answers like
- 5:57Speaker 2: I'm not sure. And when I do answers like, Okay, yeah,
- 6:02Speaker 2: you know, it's it's a high dose or medium dose.
- 6:05Speaker 2: And then when I dig deeper and when I ask them,
- 6:08Speaker 2: why do you think it's medium or high? And then
- 6:11Speaker 2: the rationale is usually oh, because that's what I'm being taught.
- 6:15Speaker 2: And what I was really hoping for was, you know,
- 6:18Speaker 2: they can really share more insights about oh because that's
- 6:22Speaker 2: the conversion, or because you know, because of this pharmacal
- 6:27Speaker 2: kinetic or dynamic, or or more of an in depth
- 6:32Speaker 2: rationale of that. But unfortunately that's not what I see.
- 6:36Speaker 2: And that brings me to the second point that why
- 6:40Speaker 2: it's so important to have us, you know, be part
- 6:43Speaker 2: of the team because with the current education system, let
- 6:48Speaker 2: it be medical school or pharmacy school, I don't think
- 6:52Speaker 2: that the education is enough to We're not giving enough
- 6:57Speaker 2: training to allow physicians or promises to like I say,
- 7:02Speaker 2: clinically evaluate the opiod dose.
- 7:05Speaker 3: Because I think for the most part.
- 7:07Speaker 2: From what I hear is that most students and residents
- 7:11Speaker 2: they only get maybe like a week of training, and
- 7:14Speaker 2: that's like a week of lecture. What really is one
- 7:18Speaker 2: week of lecture, right, And what we're dealing with is really,
- 7:22Speaker 2: you know, with the opiopandemic and opio crisis. We're looking
- 7:26Speaker 2: at high opiod doses and really sophisticated opiod doses that
- 7:31Speaker 2: sometimes it's you know where it's kind of unquestionable practice, right,
- 7:35Speaker 2: and so we need almost like a sharper eyes to
- 7:39Speaker 2: address those problems. But with that little training, I don't
- 7:43Speaker 2: think that's enough. So that's kind of what we're kind
- 7:47Speaker 2: of where we're at unfortunately. And so and the third
- 7:52Speaker 2: thing that I want to share as to why I
- 7:55Speaker 2: think we are why we're crucial in the current healthcare system,
- 8:01Speaker 2: kind of looking ahead with everything going on with AI, right,
- 8:05Speaker 2: because there's a lot of bus with AI currently and
- 8:09Speaker 2: how AI can be really integral in a lot of
- 8:13Speaker 2: healthcare areas. So I like to think that I do
- 8:18Speaker 2: not think that AI will likely replace pain management or
- 8:22Speaker 2: pallative care pharmacist. Because humans are very we're very social animals.
- 8:30Speaker 2: We want that human attention, We crave for that human
- 8:35Speaker 2: human interaction. So until the point where AI or technology
- 8:41Speaker 2: is so sophisticated to a point that it can almost replace,
- 8:46Speaker 2: you know, the human interaction like one hundred percent, I
- 8:49Speaker 2: don't think that we're we will be replaceable. And even
- 8:52Speaker 2: I would say even at a point where the because
- 8:57Speaker 2: I've seen news about the humanoids and it's something down
- 9:00Speaker 2: the pipeline, right, even when the time where the AI
- 9:05Speaker 2: technology is so sophisticated that you know, it becomes the mainstream.
- 9:09Speaker 2: That means that the real human human interaction provided by
- 9:14Speaker 2: pain management pharmacists is even going to be so rare
- 9:17Speaker 2: and the world operates with scarcity. So I think that
- 9:21Speaker 2: there is always going to be a role for us
- 9:24Speaker 2: because that human interaction I don't think is replaceable. So
- 9:28Speaker 2: with that, I think our role is so crucial. Our
- 9:31Speaker 2: job is likely going to be ever green at least
- 9:33Speaker 2: for the next ten to fifteen years. So that's us
- 9:37Speaker 2: and that's me.
- 9:38Speaker 1: Yeah, yeah, it's a good day to be a pain
- 9:40Speaker 1: management pharmacist. And I agree with so many things you said. Yeah,
- 9:44Speaker 1: I don't really remember. I don't remember how long our
- 9:47Speaker 1: pain management you know, lectures were in pharmacy school. But
- 9:50Speaker 1: I know I still have a lot to learn, especially
- 9:53Speaker 1: in regards to buprinorphine. I don't really remember learning about
- 9:57Speaker 1: it that much. It's been recently I've been learning more
- 10:00Speaker 1: and more about it. But and you mentioned the relationships
- 10:03Speaker 1: and joining the roundtables and That's huge because if you
- 10:06Speaker 1: develop a relationship with the provider where they can trust you,
- 10:09Speaker 1: then they're really going to be willing to reach out
- 10:11Speaker 1: to you, get recommendations, ask for that console so huge.
- 10:16Speaker 1: So let's get into bupernorphine. I'm so curious what you
- 10:19Speaker 1: are going.
- 10:19Speaker 3: To teach us today.
- 10:21Speaker 1: First of all, can you give us a bit of
- 10:23Speaker 1: an overview mechanism of action? Yeah, just a little bit
- 10:27Speaker 1: of overview of bupern orphine.
- 10:29Speaker 2: Absolutely. So, there's so many things about buepernorphine. I feel like,
- 10:34Speaker 2: you know, sometimes I like to joke about it. I
- 10:36Speaker 2: can talk of it for hours. But if there are
- 10:39Speaker 2: some high level highlights about buprenorphine, let's let's start with
- 10:43Speaker 2: this this fat okay, So, because so many of us
- 10:47Speaker 2: would confuse with buepernorphine it's the same as the box
- 10:51Speaker 2: zone and that's false and I hear it all the time, right,
- 10:56Speaker 2: And so when when a patient is on bupernorphine, then
- 10:59Speaker 2: either arm sets or physicians they would say, oh, the
- 11:01Speaker 2: patient is on subox zone. But there are two different things.
- 11:05Speaker 2: I like to think about using this analogy is that
- 11:09Speaker 2: like all apples are fruit, but not all fruits are apples,
- 11:14Speaker 2: so we can think about that. The bulpernorphine is the fruit.
- 11:18Speaker 2: It's more inclusive, while the subo zone it's only one
- 11:23Speaker 2: type of fruit, which is apple or grape to whatever
- 11:25Speaker 2: you want to think about it. So that's very important
- 11:28Speaker 2: because with bupernorthine there's so many formulations, there's so many
- 11:32Speaker 2: dosage form so I like to call it just bluepernor
- 11:35Speaker 2: fine just for simplistic purpose.
- 11:37Speaker 3: So that's very key. So when it.
- 11:41Speaker 2: Comes to explaining bulpernorphin, I like to I think there
- 11:47Speaker 2: are two major audience.
- 11:50Speaker 3: To explain it to.
- 11:51Speaker 2: The first group is the patients and the second group
- 11:54Speaker 2: would be the physicians and clinicians. So the reason why
- 11:57Speaker 2: I think it's very important because in the end of
- 11:59Speaker 2: the day, we want to get that ideas across to patients.
- 12:04Speaker 2: We want to let patients know in the most simplistic
- 12:08Speaker 2: and understandable way so that they can buy in. And unfortunately,
- 12:14Speaker 2: at least what I've been taught in in some ces
- 12:17Speaker 2: or you know, talking to colleagues, sometimes I would say, oh,
- 12:20Speaker 2: we have to emphasize that, to emphasize that distri patients
- 12:24Speaker 2: that bill per Northie is a partial meal agonist.
- 12:27Speaker 3: So that it works better, And to.
- 12:28Speaker 2: Me, I think that's false, because at what life circumstances
- 12:34Speaker 2: do we even use the word agonist in life?
- 12:37Speaker 3: Unless unless you're right, unless you are.
- 12:40Speaker 2: A nerd, or you have a very fancy, very deep
- 12:45Speaker 2: chemistry background, then maybe you would use the word agonists
- 12:49Speaker 2: in your life. So when it comes to explaining Bill
- 12:53Speaker 2: Pernorphi into patients, I try not to even use the
- 12:57Speaker 2: word partial meal agonist because all that the patient can
- 13:01Speaker 2: register is the word partial, and they're not going to
- 13:04Speaker 2: have any context with let it be mew or agonists.
- 13:09Speaker 3: They're not going to know.
- 13:10Speaker 2: So what happens if you tell a patient that it's
- 13:13Speaker 2: a partial mew agonist, then all that their mind will
- 13:16Speaker 2: be anchoring to is the work partial, And that means
- 13:20Speaker 2: you have to almost spend extra time to explain and
- 13:24Speaker 2: kind of go back to the drawing board telling them, oh,
- 13:27Speaker 2: it's not really partial. It is still a very polite
- 13:30Speaker 2: in great medication, I feel like that is almost setting
- 13:34Speaker 2: up yourself for failure. So when I do explain it
- 13:38Speaker 2: to patients now, I feel like, after failing it so
- 13:41Speaker 2: many times when I used to do that myself as well,
- 13:44Speaker 2: and after getting so many googly eyes, I'm like, no,
- 13:48Speaker 2: let's just not tell them it's a partial new agonist.
- 13:51Speaker 3: I would just say it's.
- 13:52Speaker 2: A opioid that works differently than the conventional opios It
- 13:56Speaker 2: is still a very potent and strong opioids issue, that
- 14:00Speaker 2: it's just that it works differently, and then that way
- 14:02Speaker 2: it's way easier for them to digest when they just
- 14:07Speaker 2: hear the most simplistic form. Now, the other thing that
- 14:11Speaker 2: I think it's also beneficial for patients to understand build
- 14:16Speaker 2: per Northine is that bullper Northine is such a hard
- 14:19Speaker 2: word to pronounce. I don't refine it as well, and
- 14:23Speaker 2: I just called BUB. I tell patients that, hey, it's
- 14:26Speaker 2: it's a medication called bueper Northine, but for simplistic purpose,
- 14:30Speaker 2: you can call it bup and we will understand. And
- 14:33Speaker 2: I know that for some of my colleagues we're called
- 14:35Speaker 2: bub as well, because I think that when we are
- 14:38Speaker 2: able to associate, when we can, when we can say
- 14:42Speaker 2: that name, then it's easier for the patient to be
- 14:46Speaker 2: adherent to the medication. It's easier for them to you know,
- 14:50Speaker 2: know and understand that medication.
- 14:53Speaker 3: So I think that's very important.
- 14:55Speaker 2: So that's everything about patient side, and then you know,
- 15:00Speaker 2: with the clinician, you know, explaining to clinician, now we
- 15:04Speaker 2: could actually use the word it's a partial mew agonist.
- 15:08Speaker 3: So one of before I.
- 15:11Speaker 2: Even dig deep into you know, the partial new agonism
- 15:15Speaker 2: and the mechanism, there's one very good resource I want
- 15:18Speaker 2: to share with you. It's a paper by doctor Lynn Webster.
- 15:23Speaker 2: It's published in twenty twenty. If you type his name
- 15:27Speaker 2: L Y N N we B S t R. Doctor
- 15:31Speaker 2: Lynn Webster and type Bill pri Northine, that paper would
- 15:34Speaker 2: came with it. That paper would come out. And it's
- 15:37Speaker 2: such a good paper. It's a very good overview of
- 15:41Speaker 2: everything Bill Pernorphine, and I highly recommend that I share
- 15:45Speaker 2: the two residents students because it's a very good resource.
- 15:49Speaker 2: So one of the biggest misconception with Bill Pernorphine and
- 15:56Speaker 2: being a partial new agonist is that it is partial
- 16:00Speaker 2: it's less effective. But that's again that's not true because
- 16:05Speaker 2: when we think about, you know, the potency of an opioid,
- 16:10Speaker 2: it has more to do than just the fact that
- 16:14Speaker 2: it's a partial meal agonist. So what really when we
- 16:18Speaker 2: think about partial mew agonists is that when the researchers
- 16:23Speaker 2: look at Bupernorphine and compared to like a full mew
- 16:27Speaker 2: opia for example, let it be morphine or oxycodone. So
- 16:31Speaker 2: those are all done in vitro and so it yes,
- 16:35Speaker 2: it does show that it's partial.
- 16:37Speaker 3: It does not induce as.
- 16:38Speaker 2: Much of an effect in virtual But when it comes
- 16:42Speaker 2: to potency, there's more than just a full MEW or
- 16:46Speaker 2: partial mew, because there's also a lot to do with
- 16:51Speaker 2: how much it binds the receptor, the affinity, and how
- 16:55Speaker 2: long it stays there. So with bilpernorphine, it's very interesting
- 17:00Speaker 2: because bupernorphine has very very high affinity to the receptors
- 17:04Speaker 2: and it also lingers. It sticks to the receptors for
- 17:08Speaker 2: a long time. That's what it's part of the package
- 17:13Speaker 2: that makes bupernorpine a very very potent opioid compared to
- 17:17Speaker 2: let it be morphine or oxycodone. So it's very important
- 17:22Speaker 2: not to think that just because we are, you know,
- 17:25Speaker 2: just because bupernorphine is a partial new wagonist. There isn't
- 17:30Speaker 2: anything partial about that. So that's very key. Now the
- 17:35Speaker 2: potency with bupernorphine on research sometimes there are some mention
- 17:42Speaker 2: about it being about twenty to fifty times more potent
- 17:46Speaker 2: compared to morphine, and there are some mentioned that it
- 17:50Speaker 2: can be as potent as one hundred times than morphine,
- 17:54Speaker 2: and if I give you more context tomorrow, that fentanyl
- 17:58Speaker 2: is one hundred times more potent than morphine. So that
- 18:01Speaker 2: means if we take the upper limit of the potency
- 18:05Speaker 2: of bill pernorphine, which is one hundred times.
- 18:08Speaker 3: I know some people would.
- 18:08Speaker 2: Disagree because it's more so like twenty to fifty, but
- 18:12Speaker 2: if we take the upper limit, that means that it
- 18:14Speaker 2: can potentially be as potent as fentanyl. And we can
- 18:19Speaker 2: talk more about the conversion later. But that's why you
- 18:24Speaker 2: know with bill pernorphine, it's really not partial.
- 18:27Speaker 3: It's it's quite potent.
- 18:29Speaker 2: We look at how you know, potent it is compared
- 18:32Speaker 2: to morphine and how it's relative to fentanyl. One last
- 18:36Speaker 2: thing I want to mention about but pernorphine is that
- 18:40Speaker 2: it has what we call a kappa antagonistic property.
- 18:43Speaker 3: And so this is very interesting because we know.
- 18:46Speaker 2: That when patients are on chronic opio they are there
- 18:51Speaker 2: is more association with depression, and that's very well studied
- 18:56Speaker 2: from anecdoptical experience as well, is that when patients are
- 19:00Speaker 2: on chronicle build therapy, a lot of times there is
- 19:03Speaker 2: depression and other disorder really induced by the fullmul opiate.
- 19:09Speaker 3: Now there are.
- 19:11Speaker 2: Actually studies that look into bilprinorphine because of that Kappal
- 19:16Speaker 2: antagonistic property, it actually can lessen it almost helps with
- 19:22Speaker 2: the depression. So in our practice when I work with
- 19:26Speaker 2: the physician in the outpatient setting, what we saw and
- 19:30Speaker 2: acdoptively is that when patient transition to from fumu opioid
- 19:35Speaker 2: to blueprinorphine, sometimes the patient will have better mood and
- 19:39Speaker 2: their energy is better. And because really of that, maybe
- 19:43Speaker 2: it's there has to be something to do with that
- 19:47Speaker 2: antagonistic property. So there's a lot of interesting facts about
- 19:52Speaker 2: bill pernorphine. That's why it's such an exciting job.
- 19:55Speaker 1: Yeah, I love learning about it and especially the benefits.
- 19:58Speaker 1: And if you can, you know, switch a medication that
- 20:01Speaker 1: would improve a patient's mood potentially reduced polypharmacy with the
- 20:05Speaker 1: need for an antidepressant, that's a win for sure. So
- 20:08Speaker 1: you've talked about one benefit of.
- 20:12Speaker 3: Yes, let's talk about some of the.
- 20:15Speaker 1: Other benefits of using it over other opioids.
- 20:19Speaker 2: Absolutely, so with bipernthin there are a couple of interesting benefits,
- 20:25Speaker 2: or we can think of it as almost like a
- 20:28Speaker 2: less scide effect, because I like to think less sid
- 20:31Speaker 2: effects is still a win. So the first thing with
- 20:37Speaker 2: bupernorthine is that there is almost like a less testosterone drop,
- 20:42Speaker 2: even though that testosterone kind of less effect to the
- 20:48Speaker 2: testoterone is really from small studies back in back in
- 20:52Speaker 2: early two thousand. So in that study they look at
- 20:56Speaker 2: sublo zone, which is a you know it dope that
- 21:00Speaker 2: is usually for patients with op use disorder or dependence
- 21:05Speaker 2: and sometimes complex pain. And in that study they look
- 21:08Speaker 2: at the bloxom compared to methodone. So what they saw
- 21:13Speaker 2: is that there is a statistical difference in terms of
- 21:17Speaker 2: testosterone decrease. So and with that, the buperenorphine group has
- 21:23Speaker 2: less testosterone drop than methodone, meaning that methadone is going
- 21:27Speaker 2: to cause more testosterone drop. Now, the other aspect of
- 21:32Speaker 2: that is that they in that study they also look
- 21:35Speaker 2: into libido and that that you know difference is quite significant.
- 21:40Speaker 2: So they saw that in the about twenty percent of
- 21:43Speaker 2: the patients in in the buperenorphiane group, there is there
- 21:49Speaker 2: is an decrease and influence of the libido, and in
- 21:53Speaker 2: the methodone group there's almost like eighty percent or something
- 21:57Speaker 2: like that.
- 21:57Speaker 3: So the difference is huge.
- 22:00Speaker 2: Now with that caveat is that because this study they're
- 22:04Speaker 2: really looking at bernorphine in a higher dose, because when
- 22:09Speaker 2: we look at the bubernorthine that comes in less you know,
- 22:13Speaker 2: in lower dose like butrains and belbuca, it's I would say,
- 22:17Speaker 2: it's kind of hard to translate that to like a
- 22:20Speaker 2: lower dose product.
- 22:22Speaker 3: So take it with a grain of salt.
- 22:24Speaker 2: So there is definitely some studies out there that look
- 22:27Speaker 2: into the testosterone influence. But again, you know, there's some
- 22:32Speaker 2: caveat in their in terms of what patient population group
- 22:35Speaker 2: they study at and also the dosing, because dosing is
- 22:40Speaker 2: everything when it comes to opioid management. Now, there are
- 22:44Speaker 2: also two big other side effects that buprenorphine has less
- 22:50Speaker 2: of an effect compared to the fullmu opuloid or the
- 22:54Speaker 2: conventional opioid. So the first one is constipation. And I
- 22:58Speaker 2: love talking about constipation with PaaS because you know what
- 23:01Speaker 2: tomorrow A lot of patients feel that talk about pope
- 23:05Speaker 2: or talk about bow movement.
- 23:06Speaker 3: It's so embarrassing. I don't know why.
- 23:10Speaker 2: Yeah, And so sometimes and just from my experience is
- 23:15Speaker 2: that patients don't talk about it.
- 23:17Speaker 3: Until things are, you know, hitting the roof. It's like day.
- 23:21Speaker 2: Four, they're not about movement and something is going south
- 23:25Speaker 2: and they tell me. So it's very important that you
- 23:28Speaker 2: keep track. So I like to tell patients that I'm
- 23:31Speaker 2: not a bow movement police. One to three days, I'm good,
- 23:35Speaker 2: because again, you know, just like paid management, with constant patient,
- 23:40Speaker 2: there's also some subjectivity subjectivity with that. It has to
- 23:45Speaker 2: do with their subjective feeling of whether or not they
- 23:48Speaker 2: feel backed up. And so if there are some subjective
- 23:51Speaker 2: factors in there, and everyone has their own vow movement pattern,
- 23:56Speaker 2: so everyone's different, but I'd like to just keep it
- 23:59Speaker 2: very broad and general. I tell them, you know, one
- 24:01Speaker 2: to three days, I'm good. Four days got to be
- 24:05Speaker 2: more watchful. In five days, probably we've got to do something.
- 24:08Speaker 2: So it's important to kind of gauge the baseline and
- 24:12Speaker 2: then you know, let them know kind of what kind
- 24:15Speaker 2: of ballpark that I'm looking for.
- 24:18Speaker 3: So with bupernorthine, there are.
- 24:19Speaker 2: Studies that look at that look at the incidents of
- 24:24Speaker 2: constipation and they compare that with morphine. So what they
- 24:27Speaker 2: found is that bupernorphine is associated with less constipation, and
- 24:32Speaker 2: perhaps there is some mechanistic explanation to that, if we
- 24:37Speaker 2: want to get to more of a biochemical reasoning of
- 24:41Speaker 2: that is that there is some there is a mechanism
- 24:46Speaker 2: called the beta arrestant and this is a very interesting mechanism.
- 24:50Speaker 2: Once the opiate binds to the mirror receptor, there is
- 24:54Speaker 2: this part of a cascade or a cellular response called
- 24:58Speaker 2: the beta arrestant, and this beta arrestant is proposed to
- 25:05Speaker 2: be doing the you know, it has to do with
- 25:07Speaker 2: a lot of the side effects with the opio So
- 25:11Speaker 2: part of that is the constipation and the other part
- 25:14Speaker 2: is also the respiratory depression. So all that is has
- 25:17Speaker 2: to do with the beta arrest in. And because of
- 25:21Speaker 2: the very fact that bill pernorphine is a partial new agonist.
- 25:25Speaker 2: So what what scientists are postulating is that the because
- 25:30Speaker 2: of almost like a less almost like a partial effect,
- 25:34Speaker 2: that it doesn't have as much of an effect to
- 25:38Speaker 2: this side effect cascade dictated by the beta arrest and
- 25:42Speaker 2: that's why maybe that's why we're seeing less of a
- 25:46Speaker 2: constipation side effects from Bill pernorthin. Now there is the
- 25:50Speaker 2: last one that is why bill pernorphine is being more
- 25:54Speaker 2: and more you know promoted and nowadays landscape is really
- 26:00Speaker 2: because of the fact that it has way less respiratory
- 26:05Speaker 2: depression compared to the fumal opioid. So this one has
- 26:10Speaker 2: to do with what we call the ceiling effect of
- 26:13Speaker 2: the pupernorthin we saw, and it's again it's due to
- 26:17Speaker 2: the partial at the partial meal agonist effect that there
- 26:21Speaker 2: is a ceiling effect that has to do that comes
- 26:24Speaker 2: with it. So what we mean by ceiling effect is
- 26:28Speaker 2: that after a certain dose of bupernorthine then it almost
- 26:32Speaker 2: like plateaus out. So the more bupernorphine you give, it's
- 26:37Speaker 2: not going to cause more respiratory depression. Now there's one
- 26:42Speaker 2: catch to that, because I don't want everyone to almost
- 26:46Speaker 2: like go go, you know, to feeling almost too safe
- 26:50Speaker 2: with dupernorphine, because there is one covenat with that is
- 26:54Speaker 2: when patients are on duprenorphine with for example, like a benzodiazepine,
- 27:00Speaker 2: it can like in that combination itself can also cause that,
- 27:05Speaker 2: you know, respiratory depression. And there is actually a study
- 27:09Speaker 2: that look into the the overdose death reports and when
- 27:15Speaker 2: they look at patients who are overdose on purely bupernorphin,
- 27:20Speaker 2: the incidence is very very low. But when they look
- 27:23Speaker 2: at patients who are on buprenorphine bought, they also found
- 27:27Speaker 2: other you know, sedatives like benzo or other sedatives in there.
- 27:31Speaker 2: That's where they saw like almost like a substantial increase
- 27:34Speaker 2: with the overdose in those cases. So that's why it's
- 27:38Speaker 2: very important that just because bupin yes, let's acknowledge that
- 27:42Speaker 2: it has a safer you know, cyber profile, let it
- 27:46Speaker 2: be constipatient or the respiratory depression, but it's still very
- 27:51Speaker 2: important to make sure that we are trying not to
- 27:56Speaker 2: use as much of a benzo when if you do,
- 27:59Speaker 2: make sure that they get Didney lock zone and be
- 28:01Speaker 2: close monitoring. So that's very very important.
- 28:05Speaker 1: Yeah, I think that makes a lot of sense, and
- 28:08Speaker 1: those are perks. Especially when we're talking about our geriatrics.
- 28:11Speaker 1: How many of them are already constipated before you put
- 28:14Speaker 1: them on any sort of paid medication, So we do
- 28:17Speaker 1: have to be vigilant about, you know, being proactive monitoring
- 28:21Speaker 1: it starting something. So I love that benefit of bupernorphine
- 28:26Speaker 1: and especially you know, the respiratory depression because our older
- 28:30Speaker 1: adults maybe already have you know, less reserve, they might
- 28:36Speaker 1: have COPD, long term asthma and you know what, they're
- 28:39Speaker 1: probably not exercising and taking a deep breath very often
- 28:43Speaker 1: and you know, doing that kind of respiratory therapy or exercise.
- 28:47Speaker 1: So those benefits are huge. And then remind me with
- 28:50Speaker 1: bupernorphine and kidney impairment liver impairment, is there any precautions
- 28:55Speaker 1: that need to be used there or can they can
- 28:57Speaker 1: do perorphine be used for kidney and liver impairment?
- 29:00Speaker 2: That is such a good question. It's almost like a
- 29:02Speaker 2: million dollar question because you know, because you know what,
- 29:07Speaker 2: like with dupreneurs In, I want to say that when
- 29:11Speaker 2: it first came out in the late sixties and almost
- 29:16Speaker 2: in seventies, there's you know a lot of studies when
- 29:19Speaker 2: when it first came out, it's it's in the I
- 29:21Speaker 2: V I M formulation.
- 29:23Speaker 3: And then after I would.
- 29:25Speaker 2: Say probably in the nineties where there's still a lot
- 29:29Speaker 2: of research and then there is almost like a gap
- 29:31Speaker 2: period where it's just almost like stopped, like everything is
- 29:35Speaker 2: about like opiate your disorder or dependence, and these studies
- 29:40Speaker 2: on pain management is lacking. And so there's almost this
- 29:44Speaker 2: this period where we don't have a lot of data
- 29:48Speaker 2: and now we're slowly picking back up, but then we
- 29:50Speaker 2: now that we're slowly picking back up, and then we
- 29:52Speaker 2: don't we were almost missing a lot.
- 29:55Speaker 3: Of data in the interim.
- 29:57Speaker 2: So I would say that's such a good question because
- 30:01Speaker 2: with the renal dysfunction and the hypatic dysfunction, there is
- 30:06Speaker 2: more data in the hypatic dysfunction population. So what we
- 30:11Speaker 2: saw is that even when we look at the drug
- 30:14Speaker 2: label itself, it says that when patients have hypatic dysfunction
- 30:20Speaker 2: in the very severere hepatic dysfunction group, there is almost
- 30:25Speaker 2: like a one hundred and eighty percent of serum level
- 30:28Speaker 2: and AAC increase compared to healthy subjects. So in those
- 30:33Speaker 2: patient populations we would recommend to, you know, going back
- 30:36Speaker 2: to the first principle of opiate dosing is start low,
- 30:40Speaker 2: go slow, and so that I feel like with the
- 30:44Speaker 2: hypatic dysfunction group, there's more data. But one of the
- 30:48Speaker 2: very interesting caveat is that the with duper nor thing,
- 30:53Speaker 2: because it has so many formulations, one formulation that is
- 30:57Speaker 2: actually recommend against and the hypatic dysfunction group is the
- 31:02Speaker 2: subo zone. And so the bulpernorthing in hipadic impairment, Yes,
- 31:08Speaker 2: we can start lowco slow and do more monitoring, but
- 31:12Speaker 2: specifically with subox on. What happens is that because subo
- 31:16Speaker 2: zone has both the bupernorthin and ny locks and co
- 31:21Speaker 2: formulated in there, what happens is the problem is in
- 31:24Speaker 2: the pupernorthine. The problem is then they lock some because
- 31:29Speaker 2: with hipadic impairment, the name lock zone is really not cleared.
- 31:35Speaker 2: So if you look at the drug label of suboxone,
- 31:37Speaker 2: it would really stay recommend against, like don't even use
- 31:41Speaker 2: it because the problem being when the when our body
- 31:45Speaker 2: is not clearing, then they lock zone. Then the fear,
- 31:48Speaker 2: the concern is that there will be causing more withdrawal symptoms.
- 31:53Speaker 2: It's almost like they locks on this in the system
- 31:56Speaker 2: for too long and it will almost like causing this
- 32:00Speaker 2: constant antagonist effect while there's the bupernorphan in the system.
- 32:05Speaker 2: So if we look into the patch insert, that is
- 32:09Speaker 2: one formulation that it would be recommended against and that
- 32:12Speaker 2: is this book zone. And with the renal dysfunction that grew. Wow,
- 32:19Speaker 2: I want to say, like there really isn't a lot
- 32:22Speaker 2: of data. I recently published a paper with balbuco use
- 32:28Speaker 2: in endstage renal disease. It's a case report and I
- 32:32Speaker 2: do that case report because I really want to tell
- 32:36Speaker 2: people out there and really start looking at start studying
- 32:39Speaker 2: in this patient population group because we don't know as much.
- 32:43Speaker 3: When we look at.
- 32:44Speaker 2: The up to date or a lexicom and go to
- 32:48Speaker 2: the kidney impairment and see if there is any dose adjustment,
- 32:52Speaker 2: they would say no adjustment. But I am a little
- 32:56Speaker 2: bit partial and I'm not quite sure about that, because
- 33:01Speaker 2: we know that with renal impairment, there is a active
- 33:06Speaker 2: metabolite from bulpernorthine. It's called nor bupernorphine. Nordupennorphine is still
- 33:13Speaker 2: considered active. If we look into the literature and in
- 33:17Speaker 2: the renal impaired patients that nordupernorphine can still be accumulated.
- 33:24Speaker 2: So now is there a load of studies and case
- 33:29Speaker 2: report out there saying that pernorphine should not be used
- 33:33Speaker 2: in renal impaired patients. No, because if we look into
- 33:38Speaker 2: like if we do aputment search or Google scholar search
- 33:42Speaker 2: and search for renal impairment and bubernorphine, they actually they
- 33:47Speaker 2: actually recommend in some of the review articles, they recommend
- 33:51Speaker 2: to use bupernorphine in renally impaired patients. But if we
- 33:56Speaker 2: go to the very if we go to the references,
- 34:00Speaker 2: we saw that a lot of that is really referencing
- 34:03Speaker 2: in you know, small studies, case reports. So that's why
- 34:08Speaker 2: in the renal patients, I feel like the data is
- 34:12Speaker 2: not enough. But am I going to say that we
- 34:16Speaker 2: should avoid using it. No, I think that we should
- 34:18Speaker 2: start using it more, but in a more careful manner,
- 34:22Speaker 2: so then we can start to gather more data because
- 34:26Speaker 2: I feel like if we want, I feel like at
- 34:28Speaker 2: this trend of the openly prescribing landscape nowadays, I feel
- 34:32Speaker 2: like the norphine is going to get more and more popularity,
- 34:37Speaker 2: and this is the time we want to really start
- 34:41Speaker 2: thinking about and really start using it in those patients.
- 34:45Speaker 2: So then we get an even more clear experience in
- 34:50Speaker 2: what we're going to do in the renally impaired patients.
- 34:54Speaker 3: Yeah.
- 34:55Speaker 1: Yeah, always with geriatrics, right, start logo slow on.
- 34:58Speaker 3: Absolutely, you can use the savor one. You got it.
- 35:02Speaker 1: So as we're talking about dosing, you know, that's one
- 35:06Speaker 1: thing where I feel like is a great area with pupernorphine.
- 35:09Speaker 1: Can you just talk about dosing and conversions from other
- 35:13Speaker 1: opioids to pupernorphine.
- 35:16Speaker 2: Yeah, And I would say conversion and dosing is another
- 35:20Speaker 2: area that is a little bit ambiguous, okay, And because
- 35:25Speaker 2: again the with albuprenorphine works being a partial meal agonist,
- 35:31Speaker 2: is that its conversion is not as straightforward as we think.
- 35:36Speaker 2: Now I'd like to think that the conversion of gupernorphine
- 35:41Speaker 2: as there are two ways to think through that. There
- 35:44Speaker 2: is a theoretical way and there's also a practical way.
- 35:49Speaker 2: So let's just start with the theoretical way and kind
- 35:51Speaker 2: of going back to the drawing board of howpernorphine is
- 35:55Speaker 2: about twenty eight to fifty times more potent than morphine,
- 35:59Speaker 2: and in some other cases in the upper limits it
- 36:02Speaker 2: can potentially be one hun times more potent me morphine.
- 36:07Speaker 2: So with that in mind, I've seen some you know,
- 36:11Speaker 2: some dosing guides that would almost convert the buperenorvhine the
- 36:17Speaker 2: bill trans patch. They convert the bill trans patch almost
- 36:21Speaker 2: very very similarly to the way we convert to the
- 36:25Speaker 2: fentanel patch. Maybe my postulation is that it's really due
- 36:29Speaker 2: to that potency. You know, how bupernorphine can potentially be
- 36:34Speaker 2: as potent as sentinel.
- 36:35Speaker 3: So I have seen that.
- 36:37Speaker 2: Now the a lot of times I still go back
- 36:41Speaker 2: to the dosing guide. There's a little table that is
- 36:46Speaker 2: provided by the Bell Bilga manufacturer. But there is some
- 36:50Speaker 2: catch that I feel like there is everything with the
- 36:53Speaker 2: conversion is is there there's some sort of caveat to
- 36:57Speaker 2: that because if we look at the how we're going
- 37:01Speaker 2: to convert patients who are on ninety to one hundred
- 37:05Speaker 2: and sixty oral morphine equivalent, they would recommend to convert
- 37:11Speaker 2: them to three hundred microgram towards the day balbuca. But
- 37:15Speaker 2: if we think about ninety to one sixty or morphinic growth,
- 37:20Speaker 2: that's a huge jump, right, And so I would wish
- 37:23Speaker 2: that if it's for example, like ninety to maybe like
- 37:27Speaker 2: one twenty, sure, but note either one sixty then just
- 37:31Speaker 2: from that range, you know that there it's almost like
- 37:36Speaker 2: it's too imprecise to put our fingers on how to
- 37:40Speaker 2: really convert from the fullmua opioid to balbuka or bil trends.
- 37:45Speaker 3: Now, the practical side of it is really what it gets.
- 37:50Speaker 2: Where it gets interesting what bulpernorphine there is something that
- 37:56Speaker 2: is quite unique to itself is that for some reason
- 38:01Speaker 2: it has to do with again the fact that it's
- 38:03Speaker 2: a partial new agonist, is that it can cause what
- 38:07Speaker 2: we call precipitated withdrawal.
- 38:09Speaker 3: And this is so interesting.
- 38:11Speaker 2: That likely because it's a you know, the intrinsic activity
- 38:16Speaker 2: because of the partial mew agonist. So there is this
- 38:20Speaker 2: phenomenon called the precipitate withdrawal. And so it happens when
- 38:25Speaker 2: a patient has been on on full full mul opiod
- 38:30Speaker 2: for some time and sometimes if they're on high dopes,
- 38:34Speaker 2: and if we start them on a you know, let
- 38:38Speaker 2: it be like a sybox on two milligrams or four
- 38:41Speaker 2: milligrams from the get go, it can cause what we
- 38:44Speaker 2: call precipitate withdrawal. And that's why there is more and
- 38:48Speaker 2: more studies starting around I would say in the last
- 38:52Speaker 2: five to ten years. That's why people start to start
- 38:57Speaker 2: to really promote this idea called mycro induction. Have you
- 39:01Speaker 2: heard of the micro induction so far? Yeah, yeah, it's
- 39:05Speaker 2: a it's a very interesting thing. So the idea of
- 39:09Speaker 2: that is because now that we know if a patient
- 39:13Speaker 2: is on this full meal opia for some time and
- 39:16Speaker 2: then you start them on like a box zone which
- 39:19Speaker 2: is the milligram dose, then it can cause that precipited
- 39:24Speaker 2: withdraw So the idea of the micro induction is that
- 39:28Speaker 2: we want to sneak in. We slowly introduce that be
- 39:33Speaker 2: pernorphing into the system with the hope that it's not
- 39:37Speaker 2: going to cause that precipited withdraw So that's what we
- 39:41Speaker 2: call the micro induction. It's it's almost like it's very sophisticated.
- 39:47Speaker 2: It takes more time compared to you know, a conventional
- 39:52Speaker 2: conversion from like a full meal to like a sybox.
- 39:56Speaker 2: And those are those when we convert from full meal
- 39:59Speaker 2: to the box on those cases are mostly for patients
- 40:03Speaker 2: who have opiuse disorder dependence, or we call it like
- 40:07Speaker 2: a complex pain picture. Now I do have patients where
- 40:13Speaker 2: they're on just maybe like you know, oxycodone, you know,
- 40:17Speaker 2: ten milligrams, you know, four times a day, or hydro codone,
- 40:21Speaker 2: and then when we convert them to when we convert
- 40:26Speaker 2: them to upernorphine, let it be trends. What I would
- 40:31Speaker 2: do is that I would start low and go slow
- 40:35Speaker 2: because something to really bear in mind is this precipitate
- 40:39Speaker 2: withdrawal side effects. It's kind of hard to predict. So
- 40:43Speaker 2: with dupern in conversion, it's that That's why I call it.
- 40:47Speaker 2: The practical side of it is it's not as straightforward
- 40:51Speaker 2: as going from one to another leg from morphine with
- 40:54Speaker 2: the lauded it's it doesn't quite operate like that.
- 40:58Speaker 3: Now, the one last thing I want.
- 40:59Speaker 2: To really talk about with the conversion, right, because when
- 41:02Speaker 2: we think about conversion, one of its use with opio
- 41:08Speaker 2: conversion is to determine the pr end dosing of the opio.
- 41:13Speaker 2: Let's say, for example, someone is you know, on certain
- 41:17Speaker 2: amount of or morphinic equivalent and then they break a hip,
- 41:21Speaker 2: and then what do we do with that, you know,
- 41:23Speaker 2: with that breakthrough pain for example, then we will start
- 41:26Speaker 2: to think about, okay, we will you know, tally up
- 41:30Speaker 2: all the total daily or morphinicquavalent and then do our
- 41:35Speaker 2: at ten to twenty percent, you know, ten to twenty
- 41:38Speaker 2: percent of total daily dose and then go from there
- 41:42Speaker 2: and then that's our PRN dose. But here's the thing
- 41:46Speaker 2: with suboxone, okay, which is the milligram dose of upnorthin
- 41:51Speaker 2: we know that that doesn't quite apply. And the reason
- 41:56Speaker 2: why is because when we really look, if we kind
- 42:01Speaker 2: of go back to the theoretical potency and conversion argument
- 42:06Speaker 2: of upernorphine, right, we know that it's about like fifty
- 42:10Speaker 2: twenty to fifty times more potent than a full meul opioid.
- 42:15Speaker 2: But if we really use that conversion and look into
- 42:20Speaker 2: how much or a morph an equivalent with like suboxone
- 42:25Speaker 2: or buprenorthian in milligrant does if we really do that math,
- 42:30Speaker 2: theoretical math, it can come to maybe like hundreds of
- 42:35Speaker 2: or a morphine equivalents. But when in practical setting, let's
- 42:39Speaker 2: say someone is indeed one suboxone, let it be twelve
- 42:43Speaker 2: sixteen milligrams and they do need to have to undergo
- 42:47Speaker 2: some sort of surgery, do we do that ten to
- 42:50Speaker 2: twenty percent? Meaning that if they're on hundreds of theoretical
- 42:55Speaker 2: or morphine equivalent, do we do we give them like
- 42:57Speaker 2: one hundred, you know, or or fifty to one hundred
- 43:01Speaker 2: or a peer in dose. We don't do that because
- 43:03Speaker 2: from my practice and mcdoctorly I would start with oxycolodone
- 43:08Speaker 2: ten maybe fifteen milligrams when patients are on subox zone.
- 43:13Speaker 2: So when we think about that really like does that
- 43:17Speaker 2: PRM ten to twenty percent apply to you subo zone?
- 43:22Speaker 3: We don't quite know.
- 43:23Speaker 2: That's why there is still a lot of things we
- 43:26Speaker 2: don't quite know. We can't really just use what we
- 43:29Speaker 2: know about opioid conversion and directly apply to bilpernorphine. Let
- 43:34Speaker 2: it be the microgram dose or the milligram dose, because
- 43:38Speaker 2: the conversion is not as straightforward, and we also know
- 43:41Speaker 2: that the pr and calculation doesn't quite reflect from what
- 43:45Speaker 2: we have been doing with let's say the formul opioid.
- 43:49Speaker 3: So far.
- 43:51Speaker 1: Yeah, I love you pernorphine. For all the benefits, one
- 43:54Speaker 1: of the negatives is certainly the dosing because every time
- 43:58Speaker 1: I look it up, I'm like, oh no, I got
- 44:00Speaker 1: to ask somebody because I don't I don't know what
- 44:02Speaker 1: I'm doing. But the great thing is you can start
- 44:06Speaker 1: low and tight right up based on you know, patients pain.
- 44:11Speaker 1: So is it complicated, yes, but you can. You can
- 44:16Speaker 1: change the dose fairly quickly, right like, you don't have
- 44:19Speaker 1: to let them be on that dose for too long
- 44:21Speaker 1: before you can tight right up.
- 44:23Speaker 3: Yeah.
- 44:23Speaker 2: So on if we think about like the big trends,
- 44:27Speaker 2: you know, there are multiple there are multiple ways with
- 44:32Speaker 2: different formulations, there are different dose increased strategy. So yes,
- 44:38Speaker 2: there it would recommend you know, you have to wait
- 44:40Speaker 2: for a few days to increase. But if we think
- 44:43Speaker 2: about the I know this is really off label and
- 44:46Speaker 2: this is again it's an acdoptal experience is that becauseperrphin,
- 44:52Speaker 2: it does have a long half life, and so we
- 44:55Speaker 2: do really want to let it sit in the system
- 44:59Speaker 2: for some time before we increase. So that's one thing
- 45:03Speaker 2: about buprenorphine and those increase is that we don't want
- 45:07Speaker 2: to increase it too aggressively.
- 45:09Speaker 3: Think of it.
- 45:10Speaker 2: Think about it almost like methadone, right, because methadone, we
- 45:13Speaker 2: know that it has a very very long half life,
- 45:17Speaker 2: and if we increase it every day, that's where you
- 45:19Speaker 2: know things can happen. But I would say I would
- 45:22Speaker 2: challenge that notion is that because we know that buprenorphine
- 45:27Speaker 2: has a safer the safer procific profile, I would say
- 45:33Speaker 2: that you can probably go more aggressive. You can increase
- 45:37Speaker 2: it more often compared to let's say a methodone.
- 45:40Speaker 3: Methodone.
- 45:41Speaker 2: We don't absolutely do not increase it unless it's five
- 45:44Speaker 2: to seven days or sometimes even longer. But with buprenorphine,
- 45:47Speaker 2: I think you can do it in a shorter amount
- 45:50Speaker 2: of time.
- 45:52Speaker 1: Yeah, I think I read three days is about is
- 45:55Speaker 1: that right? Something after about three days?
- 45:58Speaker 2: Yeah, something like that. But something to something to think
- 46:01Speaker 2: about is that it really depends on your or the
- 46:05Speaker 2: setting where you're managing it. If it's outpatient, right, If
- 46:09Speaker 2: it's outpatient, we have more grace to you know, kind
- 46:13Speaker 2: of weigh it out a monitor and do things very slowly.
- 46:18Speaker 3: But if you.
- 46:19Speaker 2: Are doing it in an in patient setting where things
- 46:23Speaker 2: are things are definitely being monitor everyone is watching like
- 46:27Speaker 2: a hawk, you can definitely have more grace to increase
- 46:31Speaker 2: it more rapidly than it than it sets in the
- 46:35Speaker 2: three days. And I think that's safe because of that
- 46:39Speaker 2: respiratory ceiling with the bipernorphin. So it kind of depends
- 46:45Speaker 2: on the setting where you're at.
- 46:47Speaker 1: One thing I love about the view trans patch is
- 46:51Speaker 1: for my nursing patients who are their pain isn't controlled
- 46:56Speaker 1: by the tremolol or the hydrocodem, but they don't really
- 46:58Speaker 1: need to go to a feedinyl patch or an oxy on.
- 47:00Speaker 1: You can use that but trans patch for even an
- 47:02Speaker 1: opioid naive patient at the five microgram dose correct.
- 47:06Speaker 2: Yeah, because like the if we think about if we
- 47:08Speaker 2: think about the but trands five and if we convert
- 47:13Speaker 2: that to the or morphine equivalent, it's it's a very
- 47:17Speaker 2: baby low dose. And so I like it because if
- 47:21Speaker 2: we think about it, how we convert almost like a
- 47:25Speaker 2: fentanyl patch then because we kind of draw the similarity
- 47:30Speaker 2: impotency of the upper limit of trans of bupernorphine and fentanyl.
- 47:35Speaker 2: So the way we convert fentanyl in the most you know,
- 47:40Speaker 2: traditional way, if we go back to how doctor Lynn
- 47:44Speaker 2: macpherson in that open conversion book, you know, we multiply
- 47:48Speaker 2: that fentanyel patch those times too, and then we we
- 47:51Speaker 2: we get the or moorph An equivalent. So meaning if
- 47:54Speaker 2: I give you one example, like a fentanyl twelve microgram patch,
- 47:58Speaker 2: if we most multiple by two, it's about twenty four
- 48:02Speaker 2: or more morphinicquivalent. And if we do the same calculation,
- 48:07Speaker 2: even though there isn't an official way to do that
- 48:10Speaker 2: for BOO trends, So if we do the same math
- 48:14Speaker 2: trick to bo trends, which is five multiplied by two,
- 48:18Speaker 2: then it's about like what ten or morphatic gronline. That's
- 48:21Speaker 2: a very very conservative dose. It's a low dose. So
- 48:24Speaker 2: for that argument, that's part of the reason why I
- 48:28Speaker 2: feel like it's you can start it with, you know,
- 48:30Speaker 2: even open naive patients, because it's such a conservative dose.
- 48:36Speaker 1: Yeah, I love that. Well, I tell you what I
- 48:38Speaker 1: have learned so much today, and there's so much I
- 48:41Speaker 1: still need to learn about viebe Brett. You've given us
- 48:44Speaker 1: a good overview, a good baseline to start learning more
- 48:47Speaker 1: and hopefully, you know, as we use it more and
- 48:50Speaker 1: learn more see the benefits, especially in our geriatric patients,
- 48:53Speaker 1: it'll be prescribed more because I keep talking about it,
- 48:56Speaker 1: but a lot of my providers still aren't prescribing it
- 48:59Speaker 1: for and so I do think with opioid stewardship and
- 49:03Speaker 1: the lower side effect profile, it will be used more.
- 49:06Speaker 1: And so as pharmacists do need to be equipped to
- 49:09Speaker 1: know the overviews, the dosings and things like that. So
- 49:12Speaker 1: thank you for sharing your wealth of information. And if
- 49:16Speaker 1: people want to reach you, where can they find you? Sinpin?
- 49:19Speaker 3: They can absolutely go to my LinkedIn page.
- 49:22Speaker 2: You know, my name is Sinpin Choo and I think
- 49:25Speaker 2: there's only one sinking out there, and so feel free
- 49:28Speaker 2: to follow my LinkedIn page. I try to share as
- 49:32Speaker 2: much of the opiate tips and also pasion stories, and
- 49:37Speaker 2: like I say, the amount of knowledge which is any
- 49:41Speaker 2: kind of opiate dosing right now is really is still
- 49:44Speaker 2: lacking because of the training, and so I try to
- 49:49Speaker 2: really be more advocate of that opiod dosing realm, because
- 49:55Speaker 2: it's so important for us to really start paying attention
- 49:59Speaker 2: not just looking at how we are going to how
- 50:03Speaker 2: we're going to address the opioid pandemic and the open crisis,
- 50:07Speaker 2: because right now there's a lot of you know, a
- 50:10Speaker 2: lot of news and a lot of push to address
- 50:16Speaker 2: the open crisis. Let it be the bossom management. But
- 50:19Speaker 2: I think one of the things that is really missing
- 50:21Speaker 2: out is how are we approaching those in opioid itself.
- 50:26Speaker 2: And so with that, you know, I do try my
- 50:28Speaker 2: very best to share as much experience and knowledge of that.
- 50:32Speaker 2: So I hope that everyone will, you know, learn more
- 50:35Speaker 2: through the stories and experience that I share online.
- 50:39Speaker 1: Yes, definitely follow sinking on LinkedIn and you will learn
- 50:41Speaker 1: a lot. So thanks everyone for listening. Have a great day.